The role of intravenous vasodilators in acute heart failure management

European Journal of Heart Failure

Volumn 16, Issue 8, 2014, Pages 827-834

  Piper, Susan ^a   McDonagh, Theresa ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute heart failure; Nitrates; Vasodilators

Indexed keywords

CENDERITIDE; CINACIGUAT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GLYCERYL TRINITRATE; HYDRALAZINE; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; MORPHINE; NESIRITIDE; NITRIC ACID DERIVATIVE; NITROPRUSSIDE SODIUM; PLACEBO; PRENALTEROL; SERELAXIN; URODILATIN; VASODILATOR AGENT; ATRIAL NATRIURETIC FACTOR; BENZOIC ACID DERIVATIVE; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN; SNAKE VENOM;

ACUTE HEART FAILURE; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); CONFUSION; CONVULSION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG TOLERABILITY; DYSPNEA; EMERGENCY CARE; HEMODYNAMICS; HUMAN; HYPERREFLEXIA; HYPOTENSION; ISCHEMIA; KIDNEY FAILURE; LOW DRUG DOSE; LUNG EDEMA; PATIENT MONITORING; PERFUSION; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; REVIEW; SHOCK; SIDE EFFECT; TACHYPHYLAXIS; TREATMENT OUTCOME; ACUTE DISEASE; HEART FAILURE; INTRAVENOUS DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, INTRAVENOUS; ATRIAL NATRIURETIC FACTOR; BENZOATES; HEART FAILURE; HUMANS; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDES; NITRATES; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RELAXIN; SNAKE VENOMS; VASODILATOR AGENTS;

EID: 84905693317     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.123     Document Type: Review

References (60)

1. Mosterd A, Hoes AW,. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146.
2. Braunschweig F, Cowie MR, Auricchio A,. What are the costs of heart failure? Europace 2011; 13 (Suppl 2): ii13-ii17.
3. Cleland JG, Khand A, Clark A,. The heart failure epidemic: exactly how big is it? Eur Heart J 2001; 22: 623-626.
4. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P,. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
5. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J,. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463.
6. Meerding WJ, Bonneux L, Polder JJ, Koopmanschap MA, van der Maas PJ,. Demographic and epidemiological determinants of healthcare costs in Netherlands: cost of illness study. BMJ (Clin Res) 1998; 317: 111-115.
7. Rodriguez-Artalejo F, Guallar-Castillon P, Banegas Banegas JR, del Rey CJ,. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J 1997; 18: 1771-1779.
8. NICOR. National Heart Failure Audit 2011/12 Annual Report. London: University College London, 2012.
9. Ramirez A, Abelmann WH,. Cardiac decompensation. New Engl J Med 1974; 290: 499-501.
10. Pang PS, Komajda M, Gheorghiade M,. The current and future management of acute heart failure syndromes. Eur Heart J 2010; 31: 784-793.
11. Leto L, Aspromonte N, Feola M,. Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review. Heart Fail Rev 2012; 19: 237-246.
12. Vizzardi E, Bonadei I, Rovetta R, D'Aloia A, Quinzani F, Curnis A, Dei CL,. When should we use nitrates in congestive heart failure? Cardiovasc Ther 2013; 31: 27-31.
13. Hollenberg SM,. Vasodilators in acute heart failure. Heart Fail Rev 2007; 12: 143-7.
14. Cotter G, Metzkor E, Kaluski E, Faigenberg Z, Miller R, Simovitz A, Shaham O, Marghitay D, Koren M, Blatt A, Moshkovitz Y, Zaidenstein R, Golik A,. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351: 389-393.
15. Cotter G, Moshkovitz Y, Milovanov O, Salah A, Blatt A, Krakover R, Vered Z, Kaluski E,. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail 2002; 4: 227-234.
16. Cotter G, Moshkovitz Y, Kaluski E, Milo O, Nobikov Y, Schneeweiss A, Krakover R, Vered Z,. The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003; 5: 443-451.
17. Sharon A, Shpirer I, Kaluski E, Moshkovitz Y, Milovanov O, Polak R, Blatt A, Simovitz A, Shaham O, Faigenberg Z, Metzger M, Stav D, Yogev R, Golik A, Krakover R, Vered Z, Cotter G,. High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema. J Am Coll Cardiol 2000; 36: 832-837.
18. Stevenson LW,. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Fail 1999; 1: 251-7.
19. Northridge D,. Frusemide or nitrates for acute heart failure? Lancet 1996; 347: 667-668.
20. Crane SD,. Epidemiology, treatment and outcome of acidotic, acute, cardiogenic pulmonary oedema presenting to an emergency department. Eur J Emerg Med 2002; 9: 320-324.
21. De Luca L, Fonarow GC, Adams KF Jr, Mebazaa A, Tavazzi L, Swedberg K, Gheorghiade M,. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Fail Rev 2007; 12: 97-104.
22. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J,. The EuroHeart Failure Survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003; 24: 464-474.
23. Fonarow GC, Corday E,. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev 2004; 9: 179-185.
24. Breidthardt T, Noveanu M, Potocki M, Reichlin T, Egli P, Hartwiger S, Socrates T, Gayat E, Christ M, Mebazaa A, Mueller C,. Impact of a high-dose nitrate strategy on cardiac stress in acute heart failure: a pilot study. J Intern Med 2010; 267: 322-330.
25. Nelson GI, Silke B, Ahuja RC, Hussain M, Taylor SH,. Haemodynamic advantages of isosorbide dinitrate over frusemide in acute heart-failure following myocardial infarction. Lancet 1983; 1: 730-733.
26. Elkayam U, Akhter MW, Singh H, Khan S, Usman A,. Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure. Am J Cardiol 2004; 93: 237-240.
27. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002; 287: 1531-1540.
28. Wakai A, McCabe A, Kidney R, Brooks SC, Seupaul RA, Diercks DB, Salter N, Fermann GJ, Pospisil C,. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013; 8:Cd005151.
29. Beltrame JF, Zeitz CJ, Unger SA, Brennan RJ, Hunt A, Moran JL, Horowitz JD,. Nitrate therapy is an alternative to furosemide/morphine therapy in the management of acute cardiogenic pulmonary edema. J Card Fail 1998; 4: 271-279.
30. Verma SP, Silke B, Hussain M, Nelson GI, Reynolds GW, Richmond A, Taylor SH,. First-line treatment of left ventricular failure complicating acute myocardial infarction: a randomised evaluation of immediate effects of diuretic, venodilator, arteriodilator, and positive inotropic drugs on left ventricular function. J Cardiovasc Pharmacol 1987; 10: 38-46.
31. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 62: e147-e239.
32. Metra M, Teerlink JR, Voors AA, Felker GM, Milo-Cotter O, Weatherley B, Dittrich H, Cotter G,. Vasodilators in the treatment of acute heart failure: what we know, what we don't. Heart Fail Rev 2009; 14: 299-307.
33. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP,. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-216.
34. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC,. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-2226.
35. Milo-Cotter O, Adams KF, O'Connor CM, Uriel N, Kaluski E, Felker GM, Weatherley B, Vered Z, Cotter G,. Acute heart failure associated with high admission blood pressure-a distinct vascular disorder? Eur J Heart Fail 2007; 9: 178-183.
36. Munzel T, Daiber A, Gori T,. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation 2011; 123: 2132-2144.
37. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M,. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. New Engl J Med 1987; 317: 799-804.
38. Elkayam U, Johnson JV, Shotan A, Bokhari S, Solodky A, Canetti M, Wani OR, Karaalp IS,. Double-blind, placebo-controlled study to evaluate the effect of organic nitrates in patients with chronic heart failure treated with angiotensin-converting enzyme inhibition. Circulation 1999; 99: 2652-2657.
39. Mehra A, Ostrzega E, Shotan A, Johnson JV, Elkayam U,. Persistent hemodynamic improvement with short-term nitrate therapy in patients with chronic congestive heart failure already treated with captopril. Am J Cardiol 1992; 70: 1310-1314.
40. Pizzulli L, Hagendorff A, Zirbes M, Fehske W, Ewig S, Jung W, Luderitz B,. Influence of captopril on nitroglycerin-mediated vasodilation and development of nitrate tolerance in arterial and venous circulation. Am Heart J 1996; 131: 342-349.
41. Watanabe H, Kakihana M, Ohtsuka S, Sugishita Y,. Preventive effects of angiotensin-converting enzyme inhibitors on nitrate tolerance during continuous transdermal application of nitroglycerin in patients with chronic heart failure. Jpn Circ J 1998; 62: 353-358.
42. Mills RM, LeJemtel TH, Horton DP, Liang C, Lang R, Silver MA, Lui C, Chatterjee K,. Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol 1999; 34: 155-162.
43. Hobbs RE, Miller LW, Bott-Silverman C, James KB, Rincon G, Grossbard EB,. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996; 78: 896-901.
44. Marcus LS, Hart D, Packer M, Yushak M, Medina N, Danziger RS, Heitjan DF, Katz SD,. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996; 94: 3184-3189.
45. Abraham WT, Lowes BD, Ferguson DA, Odom J, Kim JK, Robertson AD, Bristow MR, Schrier RW,. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4: 37-44.
46. Sackner-Bernstein JD, Skopicki HA, Aaronson KD,. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
47. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K,. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005; 293: 1900-1905.
48. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM,. Effect of nesiritide in patients with acute decompensated heart failure. New Engl J Med 2011; 365: 32-43.
49. Debrah DO, Conrad KP, Jeyabalan A, Danielson LA, Shroff SG,. Relaxin increases cardiac output and reduces systemic arterial load in. Hypertension 2005; 46: 745-750.
50. Smith MC, Danielson LA, Conrad KP, Davison JM,. Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers. J Am Soc Nephrol 2006; 17: 3192-3197.
51. Teichman SL, Unemori E, Dschietzig T, Conrad K, Voors AA, Teerlink JR, Felker GM, Metra M, Cotter G,. Relaxin, a pleiotropic vasodilator for the treatment of heart failure. Heart Fail Rev 2009; 14: 321-329.
52. Dschietzig T, Teichman S, Unemori E, Wood S, Boehmer J, Richter C, Baumann G, Stangl K,. Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail 2009; 15: 182-190.
53. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M,. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
54. Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF 2014. http://clinicaltrials.gov/show/NCT01870778 (3 March 2014).
55. Metra M, Ponikowski P, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Hua TA, Severin T, Unemori E, Voors AA, Teerlink JR,. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. Eur Heart J 2013; 34: 3128-3136.
56. Zamani P, Greenberg BH,. Novel vasodilators in heart failure. Curr Heart Fail Rep 2013; 10: 1-11.
57. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, Maggioni A, Nowack C, Mebazaa A,. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail 2012; 14: 1056-1066.
58. Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M,. Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006; 27: 2823-2832.
59. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Moiseyev VS, Forssmann WG, Hamdy AM, Meyer M,. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J 2008; 155: 1012.e1-1012.e8.
60. Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure 2014. http://clinicaltrials.gov/ct2/show/NCT01661634 (3 March 2014).